Tenax Therapeutics, Inc. insider trading

Every open-market purchase and sale by Tenax Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $6.6M 25 trades by 8 insiders 3 months later: median +61.3% (+56.1% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Tenax Therapeutics, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Tenax Therapeutics, Inc.’s insiders pay?

From February 19, 2016 to October 21, 2026, 12 insiders reported 19 open-market purchases and 0 sales not made under a pre-set plan in Tenax Therapeutics, Inc. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 20, 2025 into $2,323 by November 2, 2026, −78.8% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $11,718 (+18.4% a year), and held throughout $11,718 (+18.4%).

Copying Tenax Therapeutics, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Tenax Therapeutics, Inc.'s insiders from November 20, 2025, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 100% of the time.

Tenax Therapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Armistice Capital, LLC	Director	4	—	—	—	September 3, 2020
Adar1 Capital Management, LLC	10% owner	2	—	—	—	October 21, 2026
Giordano Christopher Thomas	CEO	2	—	—	—	September 15, 2026
Rich Stuart	Chief Medical Officer	2	—	—	—	December 10, 2025
Schneeberger Daniel	10% owner	2	—	—	—	September 2, 2026
Almenoff June Sherie	Director	1	—	—	—	November 19, 2025
Armistice Capital Master Fund Ltd.	Director	1	—	—	—	September 9, 2020
Doogan Declan	Director	1	—	—	—	September 17, 2026
Mcgauley Thomas	Interim CFO	1	—	—	—	November 19, 2025
Mitchum James P.	Director	1	—	—	—	February 19, 2016
Proehl Gerald T	Director	1	—	—	—	November 29, 2016
Staab Thomas R II	Chief Financial Officer	1	—	—	—	September 15, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Tenax Therapeutics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Tenax Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +4.3% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
November 28, 2025	3 buying	+21.3%	+4.3%	not yet

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Tenax Therapeutics, Inc. · Funds · Politicians